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ABSTRACT
Abundant evidence from large-scale clinical trials 
supports the importance of lowering low-den-
sity lipoprotein cholesterol (LDL-C) to decrease 
the risk of cardiovascular disease (CVD) events. 
The LDL-C targets in various guidelines remain 
important treatment goals but, even in trials 
where statin therapy achieves substantial reduc-
tion of LDL-C, a signiﬁcant number of CVD 
events still occur and the residual risk remains 
high. These ﬁndings suggest that lipid parame-
ters other than LDL-C, such as high-density lipo-
protein cholesterol (HDL-C), triglycerides, and 
LDL particle size, can inﬂuence the risk of CVD. 
On this basis, other strategies that can alter the 
lipid proﬁle, in particular raising HDL-C, may 
provide additional beneﬁts. Other factors such as 
HDL-C functionality and susceptibility to oxida-
tion and inﬂammatory factors can also inﬂuence 
cardiovascular risk. In addition to the modiﬁca-
tions of the lipid proﬁle, statins have cholesterol-
independent beneﬁcial pleiotropic effects. The 
contribution of these effects to event reduction 
is not yet fully understood. Recently, the body 
of evidence has expanded to support the use of 
intensive statin therapy in broader patient popu-
lations. The JUPITER trial has shown the beneﬁt 
of intensive statin treatment in low-risk subjects 
with high levels of high-sensitivity C-reactive 
protein and average levels of LDL-C. Unlike the 
setting of primary and secondary prevention, 
the results of statin trials in patients with heart 
failure have shown no clear beneﬁt in terms of 
survival. The recently published AURORA trial 
was carried out to investigate the effect of rosu-
vastatin in patients with end-stage renal disease 
undergoing chronic hemodialysis. In this trial 
no beneﬁt on cardiovascular events was shown 
with statin therapy. In conclusion, large out-
comes trials have clearly shown that statin treat-
ments have a favorable beneﬁt/risk proﬁle in a 
large range of patients at different levels of risk, 
with the exception of patients with heart failure 
and those with renal disease undergoing dialysis. 
Further evidence is needed on the role of thera-
peutic strategies on the so-called residual risk.
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INTRODUCTION
Despite signiﬁcant advances in the under-
standing of the causes and treatment of cardio-
vascular disease (CVD), it remains the leading 
cause of death worldwide.1,2 Low-density lipo-
protein cholesterol (LDL-C) is one of the most 
studied risk factors for CVD, and it is now well 
established that there is a direct correlation 
between the levels of plasma LDL-C and the risk 
of coronary artery disease.3
Over the past 20 years, the results of 
many large-scale, randomized clinical tri-
als have shown that use of statin therapy to 
lower LDL-C concentrations can signiﬁcantly 
reduce the incidence of mortality, major cor-
onary events, stroke, and the need for revas-
cularization in a broad spectrum of patients 
(Table 1).4-10 These beneﬁts are evident both in 
patients at relatively low risk, who have aver-
age cholesterol levels and no previous ath-
erosclerotic events, as well as in those who 
survived an acute myocardial infarction, had 
elevated levels of LDL-C, and other markers of 
heightened risk.10 Overall, statins reduce coro-
nary heart disease morbidity and mortality by 
approximately 30%-40%, with the magnitude 
of the effect being directly related to the abso-
lute reduction in LDL-C.10 The proportional 
reductions in major cardiovascular events 
appear to be similar irrespective of age, gender, 
preexisting CVD, or baseline levels of LDL-C or 
total cholesterol (Table 2).10
In addition, data from a meta-analysis of four 
large clinical trials investigating high-dose sta-
tins (intensive statin therapy) versus standard 
statin treatment have shown a further signiﬁcant 
beneﬁt in patients with acute coronary events or 
stable coronary heart disease, and reinforced the 
concept that for LDL-C, “the lower the better.”11 
The trials analyzed were the TNT (Treating to 
New Targets); the IDEAL (Incremental Decrease 
in End Points Through Aggressive Lipid-
Lowering); the PROVE-IT-TIMI 22 (Pravastatin or 
Atorvastatin Evaluation and Infection Therapy 
Thrombolysis in Myocardial Infarction-22); and 
the A to Z (Aggrastat to Zocor).12-15 The meta-
analysis showed a signiﬁcant 16% odds reduc-
tion of coronary death or myocardial infarction 
(9.4% vs. 8.0%; OR 0.84; 95% CI 0.77-0.91) and 
of coronary death or any cardiovascular event 
(32.3% vs. 28.8%; OR 0.84; 95% CI 0.80-0.89) 
in patients allocated to the intensive statin reg-
imen group versus those on standard therapy. 
The main beneﬁt was seen in preventing non-
fatal cardiovascular events such as myocardial 
infarction, stroke, angina, and revasculariza-
tion, although there was also a favorable trend 
Table 1. Reduction in the 5-year incidence of cardiovascular events per 1.0 mmol/L reduction in LDL-C: a meta-analysis of 
14 randomized trials of statins.10
Events
Endpoint Treatment (n=45,054) Control (n=45,002) RR (95% CI)
Any death, % 8.5 9.7 0.88 (0.84, 0.91)
Coronary heart disease death, % 3.4 4.4 0.81 (0.76, 0.85)
Nonfatal myocardial infarction, % 4.4 6.2 0.74 (0.70, 0.79)
Coronary revascularization, % 5.8 7.6 0.76 (0.73, 0.80)
Any stroke, % 3.0 3.7 0.83 (0.78, 0.88)
CI=confidence intervals; LDL-C=low-density lipoprotein cholesterol; RR=rate ratio.
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in the reduction of cardiovascular death (3.8% 
vs. 3.3%; OR 0.88; 95% CI 0.78-1.00).11
On the basis of these ﬁndings, LDL-C goals 
in clinical practice have been updated. In 
the US, the National Cholesterol Education 
Program (NCEP) guidelines recommend a goal 
of 1.8 mmol/L (70 mg/dL) in very-high-risk 
patients (established CVD with diabetes, smok-
ing, metabolic syndrome, or ≥2 major risk fac-
tors), and 2.6 mmol/L (100 mg/dL) in high- or 
moderately-high-risk patients.3 The recently 
updated European guidelines recommend a 
goal of <2.5 mmol/L in high-risk patients (or 
<2.0 mmol/L if feasible), and <3.0 mmol/L for 
all other patients.16 However, despite the evolu-
tion of these lipid management guidelines and 
the availability of highly effective LDL-lowering 




Current lipid-lowering therapy only partly 
reduces cardiovascular risk, leaving a residual 
risk of approximately two-thirds of pretreat-
ment (baseline) risk.17 Generally, the rate of 
major coronary events varies from 62% in pri-
mary prevention to 75% in secondary preven-
tion trials.18 For example, in the Scandinavian 
Simvastatin Survival Study, therapy reduced 
the relative risk of coronary events by approx-
imately 30% over 5 years, from an absolute 
risk of 28% to 19%. The event rate in the pla-
cebo group was 5.2%, and 3.8% per year in 
the treatment group.4 A cardiovascular events 
rate of 2%-3% per year is generally consid-
ered high, indicating that the treatment group 
remained at unacceptably high risk. The Heart 
Table 2. Effects of statin therapy on major coronary events according to baseline factors.10
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CHD=coronary heart disease; CI=confidence intervals; MI=myocardial infarction; RR=rate ratio.
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Protection Study (HPS), enrolling more than 
20,000 patients, had sufﬁcient power to exam-
ine the effect of treatment with simvastatin on 
a variety of cardiovascular outcomes in a broad 
range of individuals with different risk proﬁles. 
In this study, patients receiving simvastatin had 
a 19.8% cardiovascular event rate compared 
to a 22.3% event rate in control group, which 
equates to a 24% relative risk reduction in those 
treated with a statin.6 This important risk reduc-
tion was consistent in all subgroups and across 
all stratiﬁcations of baseline cholesterol levels, 
even those with LDL-C lower than 3.0 mmol/L. 
However, despite this impressive result, it is evi-
dent that 76% of the events were not prevented, 
with the residual risk being highest in diabetic 
patients with coronary artery disease.19 A similar 
ﬁnding was also observed in other trials such as 
CARE, PROSPER, and LIPID.5,20,21
It may be that this residual risk results from 
starting statin therapy too late or at too low a 
dose, or that the treatment period in clinical tri-
als is not long enough to observe the full range 
of beneﬁcial effects.18 In order to address this 
residual cardiovascular risk and further reduce 
the rate of cardiovascular events, it will be nec-
essary to gain a greater understanding of the 
contributory role of other known risk factors 
in CVD and to understand the potential that 
the nonlipid effects of statins may offer, as well 
as continuing to investigate the value of lower 
LDL-C goals.
RISK FACTORS FOR 
CARDIOVASCULAR DISEASE
The search for additional cardiovascular risk 
factors is constantly striving to improve phy-
sicians’ ability to accurately assess the risk of 
cardiovascular events and to provide the most 
appropriate care. A number of physiologic and 
behavioral risk factors for CVD are known. Non-
modiﬁable risk factors include advanced age, male 
gender, a family history of CVD, and genetic con-
ditions such as familial hypercholesterolemia. Of 
the modiﬁable risk factors, metabolic syndrome, 
cigarette smoking, and elevated high-sensitivity 
C-reactive protein (hsCRP) levels predict a high 
residual risk. Lifestyle modiﬁcations, such as diet 
and exercise, continue to have an important role 
in the primary prevention of CVD, particularly 
in obese subjects and those with the metabolic 
syndrome.22-27 Diabetes mellitus is also a strong 
predictor of adverse cardiovascular outcomes, 
and treatment with a statin is recommended for 
all patients with this condition.
In the last decade the relationship between 
lipids, inflammation, and their effect on the 
arterial wall has been the subject of consider-
able interest.28 Risk factors for atherogenesis give 
rise to a variety of stimuli which activate the 
inﬂammatory cascade; and every step in athero-
genesis is believed to involve cytokines, other 
bioactive molecules, and cells that are charac-
teristic of inflammation. These pathophysio-
logic insights provide the biological plausibility 
for the potential use of inflammatory mark-
ers as indicators or predictors of atherosclerotic 
disease. HsCRP is a marker of inflammation 
that has been shown to predict cardiovascu-
lar risk independent of major “traditional” risk 
factors such as smoking, hypertension, dia-
betes, and cholesterol levels.29,30 Several stud-
ies have demonstrated the ability of hsCRP to 
increase the predictive capacity of other risk fac-
tors.31,32 Evidence for a relationship between a 
patient’s baseline level of hsCRP and future vas-
cular risk has been increasingly demonstrated 
in studies from the USA and Europe, among 
women as well as men, elderly and middle-age 
subjects, smokers and nonsmokers, and among 
those with or without diabetes.33 HsCRP levels 
seem to have both short- and long-term pre-
dictive value.34,35 Treatment with statins lowers 
Adv Ther (2009) 26(5):469-487. 473
the concentration of hsCRP.36,37 Several studies 
carried out in patients with stable coronary dis-
ease, acute coronary syndrome, or healthy per-
sons, have shown that patients with lower hsCRP 
levels have a more favorable clinical outcome 
than those with higher hsCRP levels, regardless 
of the level of LDL-C.36,38-42
Multiple studies have also established 
that a low level of high-density lipoprotein 
cholesterol (HDL-C) is an independent risk 
factor for CVD.43-45 It has been shown that each 
1 mg/dL decrease in HDL-C is associated with 
a 2%-3% higher risk of coronary death inde-
pendent of LDL-C level.43 Low serum levels of 
HDL-C are likely associated with an increased 
cardiovascular risk because they reflect an 
increase in atherogenic lipoproteins. In addition 
to its major role in reverse cholesterol transport, 
HDL-C has many other biological activities that 
may contribute to its protective effect athero-
sclerosis including antioxidant, antinﬂamma-
tory, antithrombotic/proﬁbrinolytic (reducing 
platelet aggregation and coagulation), and vaso-
protective (facilitating vascular relaxation and 
inhibiting leukocyte chemotaxis and adhesion) 
activity.44,46 There is some evidence to support 
this hypothesis from both experimental mod-
els of atherosclerosis and clinical trials.47,48 
Therefore, low HDL-C could be considered 
a potential therapeutic target, in addition to 
aggressively lowered LDL-C, for the reduction of 
residual cardiovascular risk.49-52
First-line therapy of low HDL-C usually con-
sists of nonpharmacological interventions such 
as improved ﬁtness, smoking cessation, dietary 
changes, and weight loss. If these measures are 
unsuccessful, pharmacological therapies such as 
niacin, ﬁbrates, thiazolidinediones, or bile acid 
sequestrants may be initiated.53
Recent studies have investigated the inhibi-
tion of cholesteryl ester transfer protein (CETP) 
as a potential pharmacological approach for 
increasing HDL-C levels. Torcetrapib was the 
most advanced CETP inhibitor in development. 
However, in the ILLUSTRATE trial (Investigation 
of Lipid Management Using Coronary Ultrasound 
to Assess Reduction of Atherosclerosis by CETP 
Inhibitors and HDL Elevation), the combination 
of torcetrapib and atorvastatin was not superior 
to atorvastatin alone in reducing atheroscle-
rotic coronary plaque burden.54 The results of 
two double-blind, randomized trials in patients 
with heterozygous familial hypercholester-
olemia (RADIANCE 1) or mixed dyslipidemia 
(RADIANCE 2) using torcetrapib and atorva-
statin in combination, also showed no changes 
in the progression of carotid intima media 
thickness (CIMT) compared with the results of 
atorvastatin alone.55,56 Finally, a randomized, 
double-blind trial involving 15,067 patients at 
high cardiovascular risk (the ILLUMINATE trial) 
was terminated prematurely because patients 
allocated to the torcetrapib/atorvastatin combi-
nation arm showed an increased risk of mortal-
ity and morbidity compared with those treated 
with atorvastatin alone.57
These ﬁndings suggest that the functionality 
of HDL may be more important than HDL-C lev-
els themselves and that the relationship between 
HDL-C and cardiovascular risk is more complex 
than expected.58,59 HDL-C functionality (ie, the 
ability to perform its atheroprotective func-
tion) is partly independent of its concentration. 
Many factors can affect HDL-C functionality: 
modiﬁcations of HDL proteins and lipids such 
as advanced glycation and oxidation, changes 
in HDL-C composition and size of particles, and 
changes in the abundance of various proteins 
and lipids carried by HDL-C.58 A single com-
mon denominator reﬂecting the multiple HDL 
functions is yet to be found, preventing the 
direct measurement of each HDL-C function as 
the way to assess the atheroprotective capacity 
of HDL-C.
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Despite the highly publicized failure of torce-
trapib, the role of CETP inhibitors is still under 
evaluation to assess whether the off-target effects 
are a mechanism- or molecule-related toxic-
ity. In addition, alternative therapeutic strate-
gies for improving the functionality of HDL are 
being investigated.60
MODIFICATION OF 
CARDIOVASCULAR RISK FACTORS 
WITH ROSUVASTATIN
Effects on Atherogenic Lipid Proﬁle
Lipoproteins other than LDL-C can inﬂuence 
the development of coronary atherosclerosis 
and its response to therapy. Important compo-
nents of atherogenic lipids are triglycerides, low 
HDL-C, and small dense LDL. In the STELLAR 
trial (Statin Therapies for Elevated Lipid Levels 
Compared Across Doses to Rosuvastatin),61 the 
largest trial comparing the lipid-modifying 
efﬁcacy of statins, the greater efﬁcacy of rosu-
vastatin in reducing LDL-C compared with ator-
vastatin, simvastatin, and pravastatin across 
dose ranges has been shown. In this 6-week trial, 
2431 patients with hypercholesterolemia were 
randomized to different dosages of the four sta-
tins; 94% of patients completed the study. There 
was a significantly greater LDL-C reduction 
achieved with rosuvastatin 10 mg compared 
with atorvastatin 10 mg (% change –45.8 vs. 
–36.8; P<0.001), rosuvastatin 20 mg reduced 
LDL-C signiﬁcantly more than atorvastatin 20 
and 40 mg (% change –52.4 vs. –42.6 and –47.8; 
P<0.001 and P<0.002, respectively) and rosuva-
statin 40 mg reduced LDL-C more than atorvasta-
tin 40 mg (% change –55.0 vs. –47.8; P<0.001).
Rosuvastatin also produced a signiﬁcantly 
greater reduction in total cholesterol, simi-
lar or better reduction in triglycerides, and 
increase in HDL-C. In Table 3, the increase in 
HDL-C across dose ranges is shown; as rosuvas-
tatin doses are increased, HDL-C changes from 
baseline increase while atorvastatin produced 
smaller percentage increases in HDL-C.61 The 
rate of adverse events was similar among groups 
and ranged from 40% to 56% per group, being 
46% in the total study population. Twenty-nine 
patients had serious adverse events; the number 
per group ranged from 0 (rosuvastatin 40 mg) to 
5 (simvastatin 40 mg). The other adverse events 
reported were mild and similar across groups, as 
were changes in clinical laboratory results. The 
number of reported adverse events tended to be 
highest with higher doses. The most common 
adverse events were pain, pharyngitis, myalgia, 
and headache.
These results are supported by data presented 
from the MERCURY I study (Measuring Effective 
Table 3. Increase in HDL-C from baseline across dose ranges of statins: results from the STELLAR study.61
HDL-C change, %
Dose Rosuvastatin Atorvastatin Simvastatin Pravastatin
10 mg 7.7* 5.7 5.3 3.2
20 mg 9.5* 4.8 6.0 4.4
40 mg 9.6* 4.4 5.2 5.6
80 mg NA 2.1 6.8 NA
*Significantly different for all dose ranges.
HDL-C=high-density lipoprotein cholesterol; NA=not available.
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Reductions in Cholesterol Using Rosuvastatin 
Therapy), showing that patients who switched 
to rosuvastatin 10 mg had a signiﬁcantly greater 
improvement in their lipid parameters than 
those who remained on atorvastatin 10 mg, 
simvastatin 20 mg, or pravastatin 40 mg.62 The 
proportion of patients who achieved the Joint 
European Societies’ LDL-C goal (<116 mg/dL) 
was also signiﬁcantly greater for patients who 
switched to rosuvastatin 10 mg compared with 
patients who continued to receive atorvastatin, 
simvastatin, or pravastatin.62 MERCURY I was a 
16-week, randomized, open-label, parallel-group, 
switching study that compared the efﬁcacy of 
rosuvastatin versus atorvastatin, simvastatin, and 
pravastatin in patients with type IIa or IIb hyper-
cholesterolemia and established atherosclerosis, 
coronary heart disease, or type 2 diabetes.
Statins generally induce modest increases 
in HDL-C (5%-15%). However, it has not been 
established if this increase translates into a 
clinical beneﬁt, as statins are used primarily to 
decrease LDL-C while other therapies, usually 
in combination with statins, have been used to 
increase HDL-C.63,64
Effects on the Progression of  
Atheroscleroic Plaques
In order to provide more effective disease pre-
vention and address the residual risk of CVD, 
it is important to understand the mechanisms 
by which LDL-lowering therapies achieve their 
beneficial effects on atherosclerotic plaques. 
Therefore, imaging techniques such as intravas-
cular ultrasound (IVUS) and measurement of 
CIMT using B-mode ultrasound are increasingly 
being used in surrogate endpoint trials to under-
stand the relationship between levels of LDL-C 
and disease progression.65-69 In addition to IVUS 
and CIMT methodologies, other atherosclero-
sis imaging techniques include quantitative 
coronary angiography (QCA), carotid magnetic 
resonance imaging (MRI), and computed tomo-
graphy coronary angiography, each with its own 
inherent advantages and disadvantages.
An imaging surrogate biomarker for athero-
sclerosis needs to measure changes in plaque 
volume/burden, and/or measure changes in 
plaque composition, be easily reproducible 
and repeatable, and correlate with clinical out-
come. For many years, QCA was the standard 
imaging tool for the assessment and character-
ization of obstructed coronary arteries.65 QCA 
allows measurement of changes in the lumen of 
the vessel, and provides information through-
out the coronary tree, including branch vessels 
and distal stenosis. QCA was used in several of 
the early clinical trials of statin therapy, show-
ing a direct relationship between LDL-C levels 
and the rate of disease progression.70 However, 
it is an invasive procedure and because it is lim-
ited to providing dimensions of the lumen only, 
not the vessel wall, it is therefore unable to fully 
describe the effects of statin therapy on the 
plaque burden.71
IVUS is able to generate high-resolution 
tomographic images of the entire vessel wall as 
well as of the lumen, and has become the most 
precise method for the determination of coro-
nary atheroma burden. IVUS allows accurate 
measurement of atheroma volume and evalu-
ation of changes in atheroma burden during 
treatment.65 However, it is also an invasive tech-
nique, and composition of the atherosclerotic 
plaque can be difﬁcult to assess.
Previous studies using IVUS imaging have 
shown that intensive statin therapy is more 
effective than moderate therapy in reducing 
the progression of atherosclerosis. Results from 
the REVERSAL study (Reversing Atherosclerosis 
with Aggressive Lipid lowering), a randomized 
study comparing the effects of pravastatin 40 
mg/day versus atorvastatin 80 mg/day, provide 
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further evidence for the beneﬁcial effects of 
intensive lipid lowering.72 In this study, 502 
patients had evaluable IVUS examinations both 
at baseline and after 18 months of follow-up. 
For all IVUS measures, progression of athero-
sclerosis occurred in the moderate treatment 
cohort while plaque volume was unchanged 
in the intensive arm, indicating absence 
of progression.
In the ASTEROID study (A Study to Evaluate 
the Effect of Rosuvastatin On Intravascular 
Ultrasound Derived Coronary Atheroma 
Burden), a signiﬁcant regression of coronary 
atherosclerosis was seen with rosuvastatin 
40 mg/day in patients with coronary heart dis-
ease.73 ASTEROID was a prospective, open-label, 
blinded endpoint trial; 507 patients had an IVUS 
baseline examination, and after 24 months 349 
had evaluable serial IVUS examinations. In this 
study, the 53% reduction in LDL-C and the 
15% increase in HDL-C was associated with an 
IVUS-determined regression of –1.0% for ather-
oma volume.73 In this trial, 379 patients also 
had baseline angiograms. Of these, 292 had ≥1 
segment with ≥25% diameter stenosis permit-
ting measurement of the change in the sever-
ity of stenosis by QCA during follow-up. The 
lipid data for the QCA group were similar to 
the results for the full ASTEROID intention-to-
treat group.74 The relationship between changes 
in HDL-C and changes in percentage diameter 
stenosis or minimum lumen diameter in serial 
coronary angiographic studies of statin therapy 
are reported in Figure 1.74 Using the criterion 
of ≥10% change in percent-diameter stenosis 
for regression, 7.5% of patients showed regres-
sion whereas 89.4% showed <10% change and 
3.1% showed progression.74 This angiographic 
subanalysis of ASTEROID provided the ﬁrst evi-
dence that statin monotherapy, with a signiﬁ-
cant impact on both LDL-C and HDL-C, can 
promote regression of atherosclerosis.65
A subsequent pooled analysis of IVUS data 
from ASTEROID and REVERSAL, as well as the 
CAMELOT (Comparison of Amlodipine vs. 
Enalapril to Limit Occurrences of Thrombosis) and 
ACTIVATE (ACAT Intravascular Atherosclerosis 
Treatment Evaluation) studies, demonstrated that 
increasing HDL-C levels by >7.5% was an inde-
pendent predictor of a beneﬁcial effect of sta-
tin therapy on plaque progression.75 Substantial 
atheroma regression (≥5% reduction in atheroma 
volume) was observed in patients with lev-
els of LDL-C less than the mean (87.5 mg/dL) 
during treatment and percentage increases of 
HDL-C greater than the mean (7.5%, P<0.001). 
These ﬁndings highlighted the importance of 
both reducing atherogenic lipid levels and rais-
ing HDL-C, but supporting evidence from out-
comes studies is required to determine whether 
these changes translate into a reduction in 
cardiovascular events.75
B-mode ultrasound measurement of CIMT 
is a noninvasive tool to measure thickening 
of the intima media layer of the carotid and 
femoral arteries.65,71 Increased CIMT is associ-
ated with an increased risk of cardiovascular 
events and, as with QCA, there is a direct rela-
tionship between the extent of LDL-C lowering 
and rate of CIMT progression.76 Furthermore, 
CIMT regression has been observed in studies 
achieving intensive LDL-C lowering using high-
dose atorvastatin.77,78
The METEOR study (Measuring Effects on 
Intima-Media Thickness: an Evaluation of 
Rosuvastatin) used CIMT assessment to inves-
tigate the effect of rosuvastatin 40 mg/day in 
patients with subclinical atherosclerosis, moder-
ately elevated cholesterol levels, and a low risk of 
CVD.79 In this randomized, double-blind, placebo-
controlled study, the primary endpoint was the 
annualized rate of change in maximum CIMT. In 
these low-risk patients (Framingham 10-year risk 
<10%) with no established atherosclerosis and 
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moderately raised LDL-C levels, rosuvastatin sig-
niﬁcantly reduced the rate of progression of max-
imum CIMT over 2 years compared with placebo. 
Rosuvastatin 40 mg resulted in a 0.0014 mm/
year decrease in the mean maximum CIMT com-
pared with a progression of 0.0131 mm/year in 
placebo recipients (P<0.0001).79 Rosuvastatin was 
also associated with a 49% reduction in LDL-C 
and an 8% increase in HDL-C levels.
These results further extended the ﬁndings 
of the ASTEROID study, which had included 
high-risk patients with established coronary 
artery disease, and represented the ﬁrst time 
that a positive effect on the progression of 
atherosclerosis had been demonstrated, even 
in subjects with early signs of carotid artery 
disease and at low risk of coronary heart dis-
ease who would not usually be candidates for 
statin therapy. The ﬁndings also suggested that 
CIMT might be a useful tool to identify patients 
most likely to beneﬁt from early implementa-
tion of statin treatment, although the value of 
Figure 1. Relationship between either on-treatment level (A & C) or percentage change in HDL-C (B & D) and either 
change in percentage diameter stenosis (A & B) or minimum lumen diameter (C & D) in serial coronary angiographic 
studies of statin therapy.74 ASTEROID=A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived 
Coronary Atheroma Burden; CCAIT=Canadian Coronary Atherosclerosis Intervention Trial; HDL-C=high-density 
lipoprotein cholesterol; LCAS=Lipoprotein and Coronary Atherosclerosis Study; MAAS=Multicenter Anti-Atheroma 
Study; MARS=Monitored Atherosclerosis Regression Study; MLD=minimum lumen diameter; PLAC=Pravastatin 
Limitation Of Atherosclerosis In The Coronary Arteries; REGRESS=Regression Growth Evaluation Statin Study.
Reproduced from Ballantyne CM, et al. ASTEROID Investigators. Effect of rosuvastatin therapy on coronary artery stenoses 
assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-
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this screening approach needs to be validated in 
large, prospective studies.
Results from ASTEROID, METEOR, REVERSAL, 
and other studies conﬁrm that intensive lipid 
management can regress or slow the progres-
sion of coronary atherosclerosis. To further 
characterize the effects of rosuvastatin on ath-
erosclerosis, an ongoing trial, SATURN (Study of 
Coronary Atheroma by Intravascular Ultrasound: 
Effect of Rosuvastatin Versus Atorvastatin), will 
compare the effects of rosuvastatin 40 mg daily 
with atorvastatin 80 mg daily on atheroma vol-
ume as measured by IVUS imaging in patients 
with coronary artery disease.80 This is a phase 
4, multicenter, double-blind, parallel-group 
study with 1300 patients enrolled and 2 years 
of follow-up. Atherosclerosis progression will be 
assessed in a matched segment of a single cor-
onary artery at baseline and at the end of the 
treatment. The SATURN study will compare the 
effects of rosuvastatin and atorvastatin on the 
progression of coronary atherosclerosis, and 
provide a better understanding of the impact of 
intensive statin treatment on levels of LDL-C, 
HDL-C, and inﬂammatory markers on the prog-
nosis of atherosclerosis.80
The ﬁnding that increases in HDL-C in statin-
treated patients may play a signiﬁcant role in 
the promotion of atheroma regression should be 
considered in the selection of therapy and man-
agement of atherosclerotic artery disease. Both 
rosuvastatin and atorvastatin substantially reduce 
LDL-C but the increases of HDL-C produced 
by rosuvastatin are maintained across all dose 
ranges, whereas the effect on HDL-C of atorvas-
tatin reaches a plateau with increasing dose.61
Effects on Inﬂammatory Markers
Measuring hsCRP may help to identify sub-
jects with LDL-C levels below current treat-
ment thresholds but who are at increased risk 
of future cardiovascular events and may there-
fore beneﬁt from statin therapy. The JUPITER 
trial (Justification for the Use of statins in 
Prevention: an Intervention Trial Evaluating 
Rosuvastatin) directly addressed whether appar-
ently healthy persons with levels of LDL-C ≤3.5 
mmol/L but with elevated hsCRP (≥2.0 mg/L) 
might beneﬁt from statin therapy in terms of 
ﬁrst major cardiovascular event (cardiovascular 
death, nonfatal myocardial infarction, nonfatal 
stroke, hospitalization for unstable angina, and 
arterial revascularization procedure).81 Patients 
(n=17,802) were randomly assigned to receive 
rosuvastatin 20 mg daily or matching placebo.
This event-driven trial was prematurely 
stopped due to a clear treatment beneﬁt, after 
a median follow-up period of 1.9 years (maxi-
mum 5.0 years). Table 4 shows the baseline and 
ﬁnal values of LDL-C and hsCRP observed in 
the trial.81 Rosuvastatin treatment provided a 
signiﬁcant reduction in the rate of the primary 
endpoint and the majority of its individual 
components (Table 5).81 The risk reduction was 
nearly double that observed in previous trials, 
in which raised LDL-C levels were used as the 
enrolment criteria. The extent of risk reduction 
can also be correlated with the intensive low-
ering of LDL-C levels, which were reduced by 
50%, compared with previous trials (Figure 2). 
In terms of absolute beneﬁts, the proportion 
of patients meeting the primary endpoint was 
1.6% in the rosuvastatin arm and 2.8% in the 
placebo arm with an absolute risk reduction of 
1.2%; the proportion of patients with a cardiac 
event was 0.9% in the rosuvastatin arm and 
1.8% in the placebo arm, with an absolute risk 
reduction of 0.9%. The relative risk reductions 
were consistent in each subgroup according to 
age, race, status with regard to traditional risk 
factors, and level of risk.
In a prespeciﬁed subanalysis of the JUPITER 
study, the effects of lowering both LDL-C and 
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hsCRP levels were evaluated.82 Patients treated 
with rosuvastatin who achieved LDL-C levels 
<1.8 mmol/L experienced a 55% reduction in 
vascular events compared with placebo. A 62% 
reduction in event rate was also observed for 
rosuvastatin recipients who achieved hsCRP 
levels <2 mg/L. In patients treated with rosu-
vastatin who achieved both these levels, the 
reduction in vascular events was 65% compared 
with a 33% reduction in patients who achieved 
one or neither target.82 These analyses provide 
further insight into the mechanisms by which 
statins reduce cardiovascular risk and the role of 
their anti-inﬂammatory properties. In addition, 
rosuvastatin signiﬁcantly reduced the incidence 
of symptomatic venous thromboembolism, an 
effect independent of its beneﬁt in reducing the 
risk of arterial thrombosis.83
Rosuvastatin was generally well tolerated in 
this study, although there was an increased inci-
dence of physician-reported diabetes. However, 
no signiﬁcant difference in fasting blood glu-
cose levels or glycosuria was observed between 
the two study groups during the follow-up 





(n=8901) Rosuvastatin* Placebo† P
Median LDL-C, mg/dL 108 108 55 109 <0.001
Median hsCRP, mg/L 4.2 4.3 1.8 3.3 <0.001
*Patient numbers at 48 months for rosuvastatin arm: LDL-C n=440, hsCRP n=439.
†Patient numbers at 48 months for placebo arm: LDL-C n=414, hsCRP n=407.
hsCRP=high-sensitivity C-reactive protein; LDL-C=low-density lipoprotein cholesterol.
Table 5. JUPITER study results: primary endpoint and its components.81
Reproduced from: Ridker PM, et al. N Engl J Med. 2008;359:2195-2207. Copyright © 2008 Massachusetts Medical Society.  
All rights reserved.
   Rosuvastatin (n=8901)          Placebo (n =8901)
n
Rate per 100 
persons-year n
Rate per 100 
persons-year HR (95% CI) P
Primary endpoint* 142 0.77 251 1.36 0.56 (0.46, 0.69) <0.00001
Nonfatal MI 22 0.12 62 0.33 0.35 (0.22, 0.58) <0.00001
Nonfatal stroke 30 0.16 58 0.31 0.52 (0.33, 0.80) 0.003
Arterial revascularization 71 0.38 131 0.71 0.54 (0.41, 0.72) <0.00001
Hospitalization for unstable 
angina
16 0.09 27 0.14 0.59 (0.32, 1.10) 0.09
Any death 198 1.0 247 1.25 0.80 (0.67, 0.97) 0.02
*Nonfatal MI, nonfatal stroke, hospitalization for unstable angina, revascularization, death from cardiovascular causes.
CI=confidence intervals; MI=myocardial infarction; HR=hazard ratio.
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period. There were also no signiﬁcant differ-
ences between the two groups with regard to 
muscle weakness, newly diagnosed cancer, or 
disorders of the hematologic, gastrointestinal, 
hepatic, or renal systems.81
These ﬁndings conﬁrm that hsCRP is a sig-
nificant independent predictor of CVD risk 
and raise important questions regarding the 
wider use of statins, and choice of statin, in 
primary prevention. Since half of all vascular 
events occur in patients with normal or low 
LDL-C levels, identification of new screen-
ing tools to further reduce cardiovascular 
risk is essential. In the editorial accompany-
ing the JUPITER publication, two questions 
are highlighted: how to use hsCRP measure-
ments in daily practice, and if the indication 
for statin treatment should be expanded.84 
In JUPITER, the information on the role of 
hsCRP is limited by the fact that the trial did 
not compare subjects with and without high 
levels of hsCRP. The use of more widespread 
screening of hsCRP values must also take into 
account both the variability and the eleva-
tion that occurs with infections; abnormally-
high CRP levels do not always reflect CVD. 
However, the results of the JUPITER study are 
a step forward in the field of primary preven-
tion, even if it is important to take a careful 
look at the evidence and see how it should 
best be integrated into the existing guide-
lines.85 The scarcity of long-term safety data 
for lowering LDL-C in low-risk subjects sug-
gests a careful evaluation before prescribing 
a statin to healthy asymptomatic individuals 
for the rest of their lives. Nevertheless, it is 
likely that clinical guidelines will be revisited 
in light of these findings in order to assist 
physicians in identifying new patients most 
likely to benefit from statin therapy.
Figure 2. Primary endpoint data* from major placebo-controlled statin outcomes studies correlating risk reduction with 
LDL-C reduction. The area of the plotted symbol is proportional to the number of patients in the study. *Primary endpoint 
used for all studies, with the exception of 4S (major coronary events), HPS (major vascular event), LIPID (CHD death 
or nonfatal MI), SPARCL (major cardiovascular event). 4S=Scandinavian Simvastatin Survival Study; AF/TEX=Air 
Force/Texas Coronary Atherosclerosis Prevention Study; ALERT=Assessment of Lescol in Renal Transplantation; 
ASCOT=Anglo-Scandinavian Cardiac Outcomes Trial; ASPEN=Atorvastatin Study for the Prevention of coronary heart 
disease End points in Non–insulin-dependent diabetes mellitus; CARDS=Collaborative AtoRvastatin Diabetes Study; 
CARE=Cholesterol And Recurrent Events; HPS=Heart Protection Study; JUPITER=Justification for the Use of statins 
in Prevention: an Intervention Trial Evaluating Rosuvastatin; LDC-L=low-density protein cholesterol; LIPID=Long-term 
Intervention with Pravastatin in Ischemic Disease; LIPS=Lescol Intervention Prevention Study; PROSPER=PROspective 
Study of Pravastatin in the Elderly at Risk; SPARCL=Stroke Prevention by Aggressive Reduction in Cholesterol Levels; 
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BEYOND 
HYPERCHOLESTEROLEMIA: 
HEART FAILURE AND END-STAGE 
RENAL DISEASE
Although the benefits of statin therapy 
have been demonstrated in an increasing 
range of patients, both in primary and second-
ary prevention, there remain several groups 
at risk of cardiovascular events for whom 
statins are not yet indicated. In addition to 
lipid-lowering effects, experimental data 
indicate that rosuvastatin may also exhibit a 
wide variety of actions such as improvement 
in endothelial function, reduction of vascu-
lar inflammatory processes, antioxidation, 
and prevention of cardiac arrhythmias.86,87 
Most of these effects may target important 
components of the pathophysiology of heart 
failure, a condition where mortality remains 
high despite the widespread use of recom-
mended treatments such as angiotensin-con-
verting enzyme inhibitors and beta-blockers.88 
Data from observational studies and post-hoc 
analyses of randomized clinical trials indi-
cate that patients with chronic heart failure 
receiving statin treatment had favorable car-
diovascular outcomes both in ischemic and 
nonischemic cardiomyopathy.89,90
Recently, two large randomized trials investi-
gating statin therapy in patients with heart fail-
ure have been published. In the CORONA trial 
(Controlled Rosuvastatin Multinational Trial in 
Heart Failure), conducted in 5011 patients with 
systolic heart failure due to ischemic etiology, 
rosuvastatin 10 mg/day reduced LDL-C and 
hsCRP levels but did not provide a beneﬁt in 
terms of cardiovascular deaths, heart attacks, or 
strokes over a follow-up period of approximately 
3 years.91 However, a highly signiﬁcant reduc-
tion in cardiovascular hospitalizations in older 
patients with advanced systolic heart failure was 
observed, and based on this, guidelines from the 
European Heart Association recommend statin 
treatment for reducing cardiovascular hospital-
izations in patients with systolic heart failure of 
ischemic origin.92
The GISSI Heart Failure trial (GISSI-HF), 
which involved 4594 adults of all ages with 
chronic heart failure of any etiology, also failed 
to show any beneﬁt in clinical outcome (all-
cause death and hospitalizations for cardiovas-
cular causes) after nearly 4 years of treatment 
with rosuvastatin 10 mg daily.93 The results of 
CORONA and GISSI-HF reinforce the idea that 
beneﬁt from statin treatment appears, primar-
ily, to derive from the prevention of coronary 
artery disease; in clinical conditions where cor-
onary disease does not signiﬁcantly contribute 
to the causes of death, statins seem to be less 
effective. Furthermore, ﬁndings in populations 
without heart failure cannot be extrapolated to 
patients with heart failure. Once heart failure is 
established, statins may not improve morbidity/
mortality of these patients.94 Since the effect of 
statin withdrawal in ischemic heart failure is not 
yet known, current statin treatment should not 
be stopped in patients with heart failure on the 
basis of the evidence of CORONA and GISSI-HF 
and of the safety proﬁle of rosuvastatin.
The role of statins is also under investigation 
in patients with end-stage renal disease (ESRD). 
In these patients, CVD is the leading cause of 
death. Previous studies have shown that total 
and cardiovascular mortality were 32% and 36% 
lower, respectively, among ESRD patients receiv-
ing statins compared with those not receiv-
ing them.95 However, the recent 4D study has 
shown no improvement in mortality from sta-
tin treatment in patients with diabetes and ESRD 
receiving hemodialysis.96
The recently completed AURORA trial (A 
Study to Evaluate the Use of Rosuvastatin 
in Subjects on Regular Haemodialysis: an 
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Assessment of Survival and Cardiovascular Events) 
evaluated the effect of rosuvastatin treatment 
in a population of high-risk patients with 
ESRD.97 In this placebo-controlled study, 2776 
patients undergoing maintenance hemodialysis 
were randomized to receive rosuvastatin 
10 mg/day or placebo. Despite a significant 
reduction in LDL-C and hsCRP levels, rosuva- 
statin treatment failed to achieve the 
combined primary endpoint of death from 
cardiovascular causes, nonfatal MI, or 
nonfatal stroke (HR 0.96; 95%CI 0.84-1.11).98 
Among the components of the primary 
endpoint, a neutral effect of rosuvastatin 
therapy compared with placebo was also 
observed. Several considerations could be done 
with respects to these results: ﬁrst, the event 
rates in placebo group were lower than expected; 
furthermore, the trial, enrolling patients who 
had not been treated with statins during the 
previous 6 months, may have excluded those 
with previous cardiovascular events or at 
increased risk who were most likely to beneﬁt 
from treatment. Finally, approximately 50% of 
patients in AURORA discontinued the treatment, 
but the per-protocol analysis confirmed the 
lack of an effect of rosuvastatin on the primary 
composite endpoint. An accompanying 
editorial suggested that the most likely 
explanation for these ﬁndings is that patients 
undergoing dialysis have a different causal 
pathway for early cardiovascular events and 
death compared with the general population. 
Therefore, the beneﬁts of LDL reduction cannot 
be transferred directly from the ﬁeld of primary 
or secondary prevention to patients with renal 
disease undergoing dialysis.99
CONCLUSIONS
With the widespread adoption of sta-
tin treatment, substantial progress has been 
made in the management of hypercholester-
olemia and in reducing cardiovascular mor-
bidity and mortality in patients at high risk 
of cardiovascular events in both primary and 
secondary prevention. Outcomes from sev-
eral studies indicate a direct relation between 
cardiovascular event rate and LDL-C reduc-
tion, supporting the recommendation to treat 
patients to a definite target of LDL-C concen-
tration. Moreover, data from observational 
studies indicate that a continuous positive 
relationship exists between blood cholesterol 
concentrations and coronary artery disease, 
suggesting that there is not a lower threshold 
for lowering cholesterol.80 Indeed NCEP ATP 
III (National Cholesterol Education Program 
Adult Treatment Panel III) recommendations 
indicate that lowering LDL-C below 70 mg/dL 
may be beneficial in high-risk patients, espe-
cially in those with multiple major risk factors 
who are considered to be at very high risk.85
Advances in imaging technology have also 
provided a better understanding of the rela-
tionship between the effects of statin therapy 
on dyslipidemia and the progression of ath-
erosclerosis. While the ASTEROID study con-
firmed that intensive LDL-C lowering with 
rosuvastatin is able to induce regression of 
atherosclerosis in patients with established 
coronary artery disease,73,74 the results from 
METEOR expanded these findings across the 
disease spectrum, demonstrating that rosuva-
statin can slow the progression of atheroscle-
rosis even in asymptomatic patients with early 
disease and at low risk for CVD.79 Although 
there is not yet sufficient evidence to con-
clude that a reduction in the rate of progres-
sion of atherosclerosis in low-risk individuals 
directly translates into a reduction in clini-
cal events, the METEOR findings do highlight 
the potential disease burden in an apparently 
“low-risk” population.
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These are important ﬁndings when consid-
ered in light of the signiﬁcant residual cardio-
vascular risk that remains despite rigorous lipid 
management guidelines and effective statin 
treatment. In an effort to understand how fur-
ther reductions in cardiovascular risk may be 
achieved, the JUPITER trial assessed the effects 
of rosuvastatin on cardiovascular events in 
healthy subjects without elevated LDL-C, but 
who had raised levels of hsCRP, a known risk 
factor for coronary events.81 Rosuvastatin signif-
icantly reduced the incidence of major cardio-
vascular events compared with placebo, even 
in subgroups usually considered to be at low 
risk (eg, Framingham risk scores ≤10%, LDL-C 
≤100 mg/dL), and the trial was terminated early 
when the clear treatment beneﬁt was demon-
strated. These results raise a number of ques-
tions regarding the wider expansion of statin 
use in reducing cardiovascular risk, the role 
of hsCRP screening, and the balance between 
treatment beneﬁts and long-term safety and 
cost. Nevertheless, guidelines for primary pre-
vention will likely be reassessed in light of the 
JUPITER ﬁndings, as they provide a stimulus for 
achieving further reductions in cardiovascular 
risk and improvements in public health.100
ACKNOWLEDGMENTS
Drs Fabbri and Maggioni have received 
research support and lecture fees from Astra 
Zeneca. Editorial assistance in the preparation 
of this manuscript was provided by Andree 
Rose. Drs Fabbri and Maggioni would also like 
to thank Barbara Bartolomei Mecatti for her 
secretarial assistance.
Disclosure
Prior to peer review the manufacturers of 
rosuvastatin were offered the opportunity to 
comment on this article.
REFERENCES
Yach D, Hawkes C, Gould CL, Hofman KJ. The 1. 
global burden of chronic diseases: overcoming 
impediments to prevention and control. JAMA. 
2004;291:2616-2622.
Cardiovascular diseases. Fact sheet no. 317. Feb-2. 
ruary 2007. World Health Organization web site. 
Available at: www.who.int. Accessed April 2009.
Grundy SM, Cleeman JI, Merz CN, et al. Implica-3. 
tions of recent clinical trials for the National Cho-
lesterol Education Program Adult Treatment Panel 
III Guidelines. Circulation. 2004;110:227-239.
Scandinavian Simvastatin Survival Study Group. 4. 
Randomised trial of cholesterol lowering in 4444 
patients with coronary heart disease: the Scandi-
navian Simvastatin Survival Study (4S). Lancet. 
1994;344:1383-1389.
Lipid Study Group. Prevention of cardiovas-5. 
cular events and death with pravastatin in pa-
tients with coronary heart disease and a broad 
range of initial cholesterol levels: the Long 
Term Intervention with Pravastatin in Ischem-
ic Disease (LIPID) study group. N Engl J Med. 
1998;339:1349-1357.
Heart Protection Study Collaborative Group. MRC/6. 
BHF Heart Protection Study of cholesterol lower-
ing with simvastatin in 20536 high-risk individu-
als: a randomized placebo controlled trial. Lancet. 
2002;360:7-22.
Downs JR, Clearﬁeld M, Weis S, et al. Primary pre-7. 
vention of acute coronary events with lovastatin 
in men and women with average cholesterol lev-
els: results of AFCAPS/TexCAPS. Air Force/Texas 
Coronary Atherosclerosis Prevention Study. JAMA. 
1998;279:1615-1622.
Sacks FM, Pfeffer MA, Moye LA, et al. Cholesterol 8. 
and Recurrent Events Trial Investigators. The ef-
fect of pravastatin on coronary events after myo-
cardial infarction in patients with average choles-
terol levels. N Engl J Med. 1996;335:1001-1009.
Shepherd J, Cobbe SM, Ford I, et al. Prevention 9. 
of coronary heart disease with pravastatin in men 
with hypercholesterolemia: West of Scotland 
Coronary Prevention Study Group. N Engl J Med. 
1995;333:1301-1317.
Baigent C, Keech A, Kearney PM, et al. Cholester-10. 
ol Treatment Trialist’ (CTT) Collaborators. Efﬁca-
cy and safety of cholesterol-lowering treatment: 
484 Adv Ther (2009) 26(5):469-487.
prospective meta-analysis of data from 90,056 
participants in 14 randomised trials of statins. Lan-
cet. 2005;366:1267-1278.
Cannon CP, Steimberg BA, Murphy SA, et al. Meta-11. 
analysis of cardiovascular outcomes trials compar-
ing intensive versus moderate statin therapy. J Am 
Coll Cardiol. 2006;48:438-445.
LaRosa JC, Grundy SM, Waters DD, et al. Treat-12. 
ing to New Targets (TNT) Investigators. Inten-
sive lipid lowering with atorvastatin in patients 
with stable coronary disease. N Engl J Med. 
2005;352:1425-1435.
De Lemos JA, Blazing MA, Wiviott SD, et al. A to 13. 
Z Investigators. Early intensive vs a delayed con-
servative simvastin strategy in patients with acute 
coronary syndromes: phase Z of the A to Z trial. 
JAMA. 2004;292:1307-1316.
Cannon CP, Braunwald E, McCabe CH, et al. Prav-14. 
astatin or Atorvastatin Evaluation and Infection 
Therapy-Thrombolysis In Myocardial Infarction-22 
Investigators. Intensive versus moderate lipid low-
ering with statins after acute coronary syndrome. 
N Engl J Med. 2004;350:1495-1504.
Pedersen TR, Faergeman O, Kastelein JJ, et al. Incre-15. 
mental Decrease in End Points Through Aggressive 
Lipid Lowering (IDEAL) study group. High-dose 
atorvastatin versus usual-dose simvastatin for sec-
ondary prevention after myocardial infarction: the 
IDEAL study: a randomized controlled trial. JAMA. 
2005;294:2437-2445.
Graham I, Atar D, Borch-Johnsen K, et al. Euro-16. 
pean guidelines on cardiovascular disease pre-
vention in clinical practice: executive summary. 
Fourth Joint Task Force of the European Society 
of Cardiology and other societies on cardiovascu-
lar disease prevention in clinical practice (consti-
tuted by representatives of nine societies and by 
invited experts). Eur J Cardiovasc Prev Rehabil. 
2007;14(suppl. 2):E1-E40.
Rosensen R. Statins: can the new generation 17. 
make an impression? Expert Opin Emerg Drugs. 
2004;9:269-279.
Libby P. The forgotten majority: unﬁnished busi-18. 
ness in cardiovascular risk reduction. J Am Coll 
Cardiol. 2005;46:1225-1228.
Davidson MH. Reducing residual risk for patients 19. 
on statin therapy: the potential role of combina-
tion therapy. Am J Cardiol. 2005;96:3K-13K.
Sacks FM, Rouleau JL, Moye LA, et al. Baseline 20. 
characteristics in the Cholesterol and Recurrent 
Events (CARE) trial of secondary prevention in pa-
tients with average serum cholesterol levels. Am J 
Cardiol. 1995;75:621-623.
Shepherd J, Blauw GJ, Murphy MB, et al. Pravasta-21. 
tin in elderly individuals at risk of vascular disease 
(PROSPER): a randomized controlled trial. Lancet. 
2002;360:1623-1630.
Kelley GA, Kelley KS, Tran ZV. Aerobic exercise and 22. 
lipids and lipoproteins in women: a meta-analysis 
of randomized controlled trial. J Womens Health. 
2004;13:1148-1164.
Kelley GA, Kelley KS. Aerobic exercise and lipids 23. 
and lipoproteins in men: a meta-analysis of ran-
domized controlled trial. J Mens Health Gend. 
2006;3:61-70.
Yusuf S, Hawkan S, Ounpuu S, et al. INTERHEART 24. 
Study Investigators. Effect of potentially modiﬁable 
risk factors associated with myocardial infarction 
in 52 countries (INTERHEART Study): a case-con-
trol study. Lancet. 2004;364:937-952.
Zalesin KC, Franklin BA, Miller WM, Peterson ED, 25. 
McCullough PA. Impact of obesity on cardiovas-
cular disease. Endocrinol Metab Clin North Am. 
2008;37:663-684, ix.
Poirier P, Giles TD, Bray GA, et al. Obesity and car-26. 
diovascular disease: pathophysiology, evaluation, 
and effect of weight loss. Arterioscler Thromb Vasc 
Biol. 2006;26:968-976.
Scaglione R, Argano C, Di Chiara T, Licata G. Obes-27. 
ity and cardiovascular risk: the new public health 
problem of worldwide proportions. Expert Rev Car-
diovasc Ther. 2004;2:203-212.
Ross R. Atherosclerosis - an inﬂammatory disease. 28. 
N Engl J Med. 1999;340:115-126.
Pearson TA, Mensach GA, Alexander RW. Markers 29. 
of inﬂammation and cardiovascular disease: appli-
cation to clinical and public health practice: a state-
ment for healthcare professionals from the Center 
for Disease Control and Prevention and the American 
Heart Association. Circulation. 2003;107:499-511.
Ridker PM. High-sensitivity C reactive protein: po-30. 
tential adjunct for global risk assessment in the pri-
mary prevention of cardiovascular disease. Circula-
tion. 2001;103:1813-1818.
Ridker PM, Rifai N, Rose L, et al. Comparison of C 31. 
reactive protein and low density lipoprotein cho-
lesterol levels in the prediction of ﬁrst cardiovascu-
lar events. N Engl J Med. 2002;347:1557-1565.
Adv Ther (2009) 26(5):469-487. 485
Pai JK, Pischon T, Ma J, et al. Inﬂammatory markers 32. 
and the risk of coronary heart disease in men and 
women. N Engl J Med. 2004;351:2599-2610.
de Ferranti SD, Rifai N. C-reactive protein: a non-33. 
traditional serum marker of cardiovascular risk. 
Cardiovasc Pathol. 2007;16:14-21.
Ridker PM, Glynn RJ, Hennekens CH. C-reactive 34. 
protein: adds to the predictive value of total and 
HDL cholesterol in determining risk of ﬁrst myo-
cardial infarction. Circulation. 1998;97:2007-2011.
Ridker PM. C reactive protein and the prediction 35. 
of cardiovascular events among those at interme-
diate risk moving an inﬂammatory hypothesis to-
ward consensus. J Am Coll Cardiol. 2007;49:2129-
2138.
Ridker PM, Cannon CP, Morrow D, et al. Prav-36. 
astatin or Atorvastatin Evaluation and Infection 
Therapy - Thrombolysis in Myocardial Infarction 
(PROVE-IT-TIMI 22) Investigators. C-reactive pro-
tein levels and outcomes after statin therapy. N 
Engl J Med. 2005;352:20-28.
Field KM. Effect of 3-hydroxy-3-methylglutaryl 37. 
coenzyme A reductase inhibitors on high-sensi-
tivity C-reactive protein levels. Pharmacotherapy. 
2005;25:1365-1377.
Sakkinen P, Abbott RD, Curb JD, et al. C-reactive 38. 
protein and myocardial infarction. J Clin Epidemi-
ol. 2002;55:445-451.
Ray KK, Cannon CP. The potential relevance 39. 
of the multiple lipid independent (pleiotrop-
ic) effects of statins in the management of 
acute coronary syndromes. J Am Coll Cardiol. 
2005;46:1425-1433.
Ridker PM, Rifai N, Clearfield M, et al. Meas-40. 
urement of C-reactive protein for the target-
ing of statin therapy in the primary preven-
tion of acute coronary events. N Engl J Med. 
2001;344:1959-1965.
Morrow DA, de Lemos JA, Sabatine MS, et al. 41. 
Clinical relevance of C-reactive protein during 
follow up of patients with acute coronary syn-
dromes in the Aggrastat-to-Zocor Trial. Circula-
tion. 2006;114:281-288.
Ridker PM, Morrow DA, Rose LM, et al. Relative ef-42. 
ﬁcacy of atorvastatin 80 mg and pravastatin 40 mg 
in achieving the dual goals of low density lipopro-
tein cholesterol <70 mg/dl and C-reactive protein 
<2 mg/dl: an analysis of the PROVE-IT TIMI-22 tri-
al. J Am Coll Cardiol. 2005;45:1644-1648.
Gordon DJ, Rifklnd BM. High density lipoprotein - 43. 
the clinical implications of recent studies. N Engl J 
Med. 1989;321:1311-1316.
Assmann G, Gotto AM Jr. HDL cholesterol and 44. 
protective factors in atherosclerosis. Circulation. 
2004;109(suppl. 1):iii8-iii14.
Castell WP, Garrison RJ, Wilson PW, et al. Inci-45. 
dence of coronary heart disease and lipoprotein 
cholesterol levels: the Framingham study. JAMA. 
1986;256:2835-2838.
Shah PK, Kaul S, Nilsson J, et al. Exploiting the vas-46. 
cular protective effects of high density lipoprotein 
and its apolipoproteins: an idea whose time for test-
ing is coming part I. Circulation. 2001;104:2376-
2383.
Badimon J, Fuster V. Regression of atherosclerotic 47. 
lesions by high density lipoprotein plasma frac-
tion in the cholesterol-fed rabbit. J Clin Invest. 
1990;85:1234-1241.
Barter P, Gotto AM, LaRosa JC, et al. Treating to 48. 
New Targets Investigators. HDL cholesterol, very 
low levels of LDL cholesterol and cardiovascular 
events. N Engl J Med. 2007;357:1301-1310.
Linsel Nitsche P, Tall AR. HDL as a target in the 49. 
treatment of atherosclerotic cardiovascular disease. 
Nat Rev Drug Discov. 2005;4:193-205.
Chapman MJ. Therapeutic elevation of HDL-50. 
cholesterol to prevent atherosclerosis and coro-
nary artery disease. Pharmacol Ther. 2006;11:893- 
908.
Barter P, Gotto AM, LaRosa JC, et al. HDL choles-51. 
terol, very low levels of LDL cholesterol and car-
diovascular events. N Engl J Med. 2007;357:1301-
1310.
Singh IM, Shishehbor MH, Ansell BJ. High-density 52. 
lipoproteins as a therapeutic target: a systematic re-
view. JAMA. 2007;298:786-798.
Hausenloy DJ, Yellon DM. Targeting residual car-53. 
diovascular risk: raising high-density lipoprotein 
cholesterol levels. Heart. 2008;94:706-714.
Nissen S, Tardiff JC, Nicholls S, et al. Effect of the 54. 
torcetrapib on the progression of coronary athero-
sclerosis. N Engl J Med. 2007;356:1304-1316.
Kastelein JJ, van Leuven SI, Burgess L, et al. Effect 55. 
of torcetrapib on carotid atherosclerosis in famil-
ial hypercholesterolemia. N Engl J Med. 2007;356: 
1620-1630.
486 Adv Ther (2009) 26(5):469-487.
Bots ML, Visseren FL, Evans GW, et al. RADIANCE 56. 
2 Investigators. Torcetrapib and carotid intima-me-
dia thickness in mixed dyslipidemia (RADIANCE 
2 Study): a randomized double-blind trial. Lancet. 
2007;370:153-160.
Barter PJ, Caulﬁeld M, Eriksson M, et al. ILLU-57. 
MINATE Investigators. Effects of Torcetrapib in 
patients at high risk for coronary events. N Engl J 
Med. 2007;357:2109-2122.
Ansell BJ, Watson KE, Fogelman AM, et al. High 58. 
density lipoprotein function recent advances. J Am 
Coll Cardiol. 2005;46:1792-1798.
Ansell BJ, Fonarow GC, Fogelman AM. High den-59. 
sity lipoprotein: is it always atheroprotective? Curr 
Atheroscler Rep. 2006;8:405-411.
Nicholls SJ. HDL: still a target for new therapies? 60. 
Curr Opin Investig Drugs. 2008;9:950-956.
Jones P, Davidson MH, Stein EA, et al. STELLAR 61. 
study group. Comparison of the efﬁcacy and 
safety of rosuvastatin versus atorvastatin, simv-
astatin and pravastatin across doses (STELLAR 
Trial). Am J Cardiol. 2003;92:152-160.
Schuster H, Barter PJ, Stender S, et al. Effective 62. 
Reductions In Cholesterol Using Rosuvastatin 
Therapy I study group. Effect of switching statins 
on achievement of lipid goals: Measuring Effec-
tive Reductions in Cholesterol Using Rosuvas-
tatin Therapy (MERCURY I) study. Am Heart J. 
2004;147:705-713.
Brown BG, Zhao XQ, Chait A, et al. Simvastatin 63. 
and niacin, antioxidant vitamins, or the combina-
tion for the prevention of coronary disease. N Engl 
J Med. 2001;345:1583-1592.
Chapman MJ. Are the effect of statins on HDL 64. 
cholesterol clinically relevant? Eur Heart J Suppl. 
2004;6(suppl. C):c58-c63.
Nicholls SJ. Rosuvastatin and progression of 65. 
atherosclerosis. Expert Rev Cardiovasc Ther. 
2008;6:925-933.
Bots ML. Carotid intima-media thickness as 66. 
a surrogate marker for cardiovascular disease 
in intervention studies. Curr Med Res Opin. 
2006;22:2181-2190.
Davidson MH, Dembowski E. Atherosclerosis sur-67. 
rogate imaging trials come of age: for better or for 
worse? Curr Cardiol Rep. 2008;10:521-525.
Nash DT. Use of vascular ultrasound in clinical tri-68. 
als to evaluate new cardiovascular therapies. J Natl 
Med Assoc. 2008;100:222-229.
Kastelein JJP, de Groot E. Ultrasound imaging tech-69. 
niques for the evaluation of cardiovascular thera-
pies. Eur Heart J. 2008;29:849-858.
Ballantyne CM. Clinical trial endpoints: angi-70. 
ograms, events and plaque instability. Am J Car-
diol. 1998;82:5M-11M.
Tardif J-C, Heinonen T, Orloff D, Libby P. Vascu-71. 
lar biomarkers and surrogates in cardiovascular 
disease. Circulation. 2006;113:2936-2942.
Nissen SE, Tuzcu EM, Schoenhagen P, et al. RE-72. 
VERSAL Investigators. Effect of intensive compared 
with moderate lipid-lowering therapy on progres-
sion of coronary atherosclerosis. A randomized 
controlled trial. JAMA. 2004;291:1071-1080.
Nissen SE, Nicholls SJ, Sipahi I, et al. ASTEROID 73. 
Investigators. Effect of very high-intensity statin 
therapy on regression of coronary atherosclerosis: 
the ASTEROID trial. JAMA. 2006;295:1556-1565.
Ballantyne CM, Raichlen JS, Nicholls JS. ASTER-74. 
OID Investigators. Effect of rosuvastatin therapy 
on coronary artery stenoses assessed by quantita-
tive coronary angiography: a study to evaluate the 
effect of rosuvastatin on intravascular ultrasound-
derived coronary atheroma burden. Circulation. 
2008;117:2458-2466.
Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-75. 
density lipoprotein cholesterol and regression of 
coronary atherosclerosis. JAMA. 2007;297:499-508.
Amarenco P, Labreuche J, Lavallee P, Touboul PJ. 76. 
Statins in stroke prevention and carotid atheroscle-
rosis: systematic review and up-to-date meta-analy-
sis. Stroke. 2004;35:2902-2009.
Smilde TJ, van Wissen S, Wollersheim H, et al. 77. 
Effect of aggressive versus conventional lipid 
lowering on Atherosclerosis Progression in Fa-
milial Hypercholesterolemia (ASAP): a prospec-
tive, randomised, double-blind trial. Lancet. 
2001;357:577-581.
Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Ar-78. 
terial Biology for the Investigation of the Treatment 
Effects of Reducing Cholesterol: a randomized trial 
comparing the effects of atorvastatin and pravas-
tatin on carotid intima medial thickness. Circula-
tion. 2002;106:2055-2060.
Crouse JR, Raichlen JS, Riley WA, et al. METEOR 79. 
Study Group. Effect of rosuvastatin on progres-
sion of carotid intima-media thickness in low risk 
individuals with subclinical atherosclerosis. JAMA. 
2007;297:1344-1353.
Adv Ther (2009) 26(5):469-487. 487
Nicholls SJ, Raichlen JS, Ballantyne CM, et al. 80. 
Intravascular ultrasound evaluation of the effect 
of rosuvastatin versus atorvastatin on progres-
sion of coronary atherosclerosis: design of the 
SATURN study. Atheroscler Suppl. 2008;9:202. 
Abstract PO48:746
Ridker PM, Danielson E, Fonseca FAH, et al. JUPI-81. 
TER study group. Rosuvastatin to prevent vascular 
events in men and women with elevated C-reactive 
protein. N Engl J Med. 2008;359:2195-2207.
Ridker PM, Danielson E, Fonseca FAH, et al. Reduc-82. 
tion in C-reactive protein and LDL cholesterol and 
cardiovascular event rates after initiation of rosu-
vastatin: a prospective study of the JUPITER trial. 
Lancet. 2009;373:1175-1182.
Glynn RJ, Danielson E, Fonseca FAH, et al. A ran-83. 
domized trial of rosuvastatin in the prevention of 
venous thromboembolism. N Engl J Med. 2009 
Mar 29. 2009;360:1851-1861.
Hlatky MA. Expanding the orbit of primary pre-84. 
vention: moving beyond JUPITER. N Engl J Med. 
2008;359:2280-2282.
Executive Summary of the Third Report of the Na-85. 
tional Cholesterol Education Program (NCEP) Ex-
pert Panel on the Detection, Evaluation and Treat-
ment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III). JAMA. 2001;285:2486-2497.
Soran H, Durrington P. Rosuvastatin: efﬁcacy, 86. 
safety and clinical effectiveness. Expert Opin 
Pharmacother. 2008;9:2145-2160.
Kostapanos MS, Milionis HJ, Elisaf MS. An over-87. 
view of the extra-lipid effects of rosuvastatin. 
J Cardiovasc Pharmacol Ther. 2008;13:157-174.
Ramasubbu K, Estep J, White DL, et al. Experimen-88. 
tal and clinical basis for the use of statins in pa-
tients with ischemic and nonischemic cardiomy-
opathy. J Am Coll Cardiol. 2008;5:415-426.
Levy WC. Observational studies of statins in systo-89. 
lic heart failure. Heart Fail Clin. 2008;4:201-208.
Krum H, Latini R, Maggioni AP, et al. Statins and 90. 
symptomatic chronic systolic heart failure: a post-
hoc analysis of 5010 patients enrolled in Val-HeFT. 
Int J Cardiol. 2007;119:48-53.
Kjeskus J, Apetrei E, Barrios V, et al. CORONA 91. 
Group. Rosuvastatin in older patients with systolic 
heart failure. N Engl J Med. 2007;357:2248-2261.
Task Force for Diagnosis and Treatment of Acute 92. 
and Chronic Heart Failure 2008 of European Society 
of Cardiology, Dickstein K, Cohen-Solal A, et al. ESC 
Guidelines for the diagnosis and treatment of acute 
and chronic heart failure 2008: the Task Force for 
the Diagnosis and Treatment of Acute and Chronic 
Heart Failure 2008 of the European Society of Car-
diology. Developed in collaboration with the Heart 
Failure Association of the ESC (HFA) and endorsed 
by the European Society of Intensive Care Medicine 
(ESICM). Eur Heart J. 2008;29:2388-2442.
GISSI-HF Investigators, Tavazzi L, Maggioni AP, et 93. 
al. Effect of rosuvastatin in patients with chronic 
heart failure (the GISSI-HF trial): a randomized, 
double-blind, placebo-controlled trial. Lancet. 
2008;372:1231-1239.
Fornarow G. Statins and n-3 supplementation in 94. 
heart failure. Lancet. 2008;37:1195-1196.
Selger SR, Weiss NS, Gillen DL, et al. HMG CoA 95. 
reductase inhibitors are associated with re-
duced mortality in ESRD patients. Kidney Int. 
2002;61:297-304.
Wanner C, Krane V, 96. März W, et al. German Diabe-
tes and Dialysis Study Investigators. Atorvastatin 
in patients with type 2 diabetes mellitus undergo-
ing hemodialysis. N Engl J Med. 2005;353:238-248.
Fellström B, Zannad F, Schmieder R, et al. AURORA 97. 
study group. Effect of rosuvastatin on outcomes in 
chronic haemodialysis patients: design and ration-
ale of the AURORA study. Curr Control Trials Car-
diovasc Med. 2005;6:9.
Fellström BC, Jardine AG, Schmieder RE, et al. 98. 
Rosuvastatin and cardiovascular events in pa-
tients undergoing hemodialysis. N Engl J Med. 
2009;360:1395-1407.
Strippoli GFM, Craig JC. Sunset for statins after 99. 
AURORA. N Engl J Med. 2009;360:1455-1457.
Mora S, Musunuru K, Blumenthal RS. The clinical 100. 
utility of high-sensitivity C-reactive protein in car-
diovascular disease and the potential implication 
of JUPITER on current practice guidelines. Clin 
Chem. 2009;55:219-228.
